Pardes Biosciences Announces Closing of Tender Offer
August 31, 2023 08:15 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite...
Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights
July 17, 2023 07:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) today announced that it has entered into a definitive merger agreement whereby MediPacific, Inc....
Pardes Biosciences Reports First Quarter 2023 Financial Results
May 05, 2023 16:01 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended March 31, 2023. “As previously announced this...
Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19
April 03, 2023 08:00 ET
|
Pardes Biosciences, Inc
Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit of detection for infectious SARS-CoV-2 on day 3 of treatment with pomotrelvir vs. placebo ...
Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 14, 2023 16:01 ET
|
Pardes Biosciences, Inc
Data from ongoing Phase 2 trial evaluating pomotrelvir (formerly known as PBI-0451) for the treatment of COVID-19 expected in the coming weeks Cash to fund operations for the next twelve months ...
Pardes Biosciences to Present at SVB Securities Global Biopharma Conference
February 01, 2023 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 07, 2022 16:01 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug...
Pardes Biosciences to Present at Jefferies London Healthcare Conference
November 01, 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors
September 14, 2022 08:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral...
Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections
September 13, 2022 08:00 ET
|
Pardes Biosciences, Inc
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1...